Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1
Andrew Fensome, Catherine M. Ambler, Eric P. Arnold, Mary Ellen Banker, James D. Clark, Martin E. Dowty, Ivan Efremov, Andrew C. Flick, Brian S. Gerstenberger, Roger S. Gifford, Ariamala Gopalsamy, Martin Hegen, Jason Jussif, David C. Limburg, Tsung H. Lin, Betsy S. Pierce, Raman Sharma, John I. Trujillo, F.F. Vajdos, Fabien Vincent, Zhao‐Kui Wan, Li Xing, Xiaojing Yang, Xin Yang
Topics & Concepts
ChemistryADMEStereochemistryCombinatorial chemistrySelectivityPyrimidineStructure–activity relationshipIn vitroBiochemistryCatalysisCytokine Signaling Pathways and InteractionsPharmacological Effects of Natural Compoundsinterferon and immune responses